Neuronetics, Inc. (NASDAQ: STIM) announced a significant coverage expansion for its NeuroStar transcranial magnetic ...
The FDA has granted 510(k) clearance and a label expansion for a transcranial magnetic stimulation device to treat patients ...
Q3 2025 Earnings Call Transcript November 4, 2025 Neuronetics, Inc. misses on earnings expectations. Reported EPS is $-0.13438 EPS, expectations were $-0.12. Operator: Good day, and thank you for ...
Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% ...
Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, is setting the standard for TMS therapy in Colorado ...
MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life ...
Moment of Clarity has released a new resource titled “What to Know About TMS Therapy for PTSD“, now available on their website. The article provides an overview of how transcranial magnetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback